CASP3 and central nervous system cancer: An elevation in the Les-3288 dose from 0.5 to 1.0 μg/mL led to an increase in the amount of the cleaved Caspase-3 in treated glioma U251 cells, while the effect of TMZ did not change with increasing its dose from 10 and 60 μg/mL (Figure 3).